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ABSTRACT
Within the context of a globalising agenda for genetic research
where ‘global health’ is increasingly seen as necessarily informed by
and having to account for genomics, the focus on rare genetic
diseases is becoming prominent. Drawing from ethnographic
research carried out separately by both authors in Brazil, this paper
examines how an emerging focus on two different arenas of rare
genetic disease, cancer genetics and a class of degenerative
neurological diseases known as Ataxias, is subject to and a product
of the dynamics of inclusion and exclusion as this concerns
participation in research and access to health care. It examines how
in these different cases ‘rarenesss’ has been diversely situated and
differently politicised and how clinicians, patients and their families
grapple with the slippery boundaries between research, rights to
health and the limits of care, therapy or prevention. It illustrates
how attention to rare genetic disease in Brazil emerges at the
intersection of a particular history of genetic research and public
health infrastructure, densely complicated feedback loops between
clinical care and research, patient mobilisation around the
‘judicialisation’ of health and recent state legislation regarding rare
disease in Brazil. It highlights the relevance of local conﬁgurations in
the way rare genetic disease is being made relevant for and by
different communities.
KEYWORDS
Brazil; genetics; rare disease;
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INTRODUCTION
Deﬁnitions of rare disease are internationally variable, often deﬁned in terms of preva-
lence and sometimes further qualiﬁed with reference to conditions that are ‘life threaten-
ing’ or ‘chronically debilitating’. WHO ﬁgures suggest that 8% of the world’s population
are affected by rare genetic disease and there are between 6000 and 7000 rare diseases
worldwide. With 80% of rare diseases thought to be genetic in origin and many related to
single gene disorders, a focus on rare disease has long been part of genetic medicine. This
is now being extended across national and transnational terrains of health care and
research. This is evident as much in the expanded scope for newborn genetic screening in
the US and the UK aimed at including a wider range of rare potentially disabling
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conditions (Timmermans and Buchbinder 2012) as it is in high-proﬁle developments such
as the UK’s 100,000 Genomes Project. In both cases, rare genetic disease is explicitly
described as the ‘ideal platform for translational medicine and the application of high
throughput genomics in routine NHS practice’ (Strategic Priorities Working Group for
the 100K Genome Project 2013).1 At the same time, a focus on rare genetic disease var-
iants is considered important in efforts to extend the global diversity of genomic research
(Bustamente, De la Vega, and Burchard 2011).2
The role of patient organisations has also been central in reframing the social and polit-
ical signiﬁcance of rare genetic disease and in some cases the scientiﬁc trajectory of
research, particularly in Europe and North America (Rabeharisoa and Callon 2004).
While the ‘activism’ at stake in patient organisations is varied (Epstein 2008), it has, in
some cases, resulted in the productive alignment between rare disease and patient exclu-
sion. This has transformed ‘uncommon disorders’ into ‘rare diseases’ (Huyard 2009) and
lead to changes in the regulation of clinical trials involving so called ‘orphan drugs and
diseases’ in the US and Europe.3 However, as Rabeharisoa et al. (2014) point out, various
strategies of politicisation can be identiﬁed within diverse patient organisations focused
on rare and genetic disease with consequences for the scope and limits of research and
resources across different national arenas, particularly in the US and Europe.
Drawing from ethnographic research carried out separately by both authors in Brazil, a
neglected region outside of Europe and North America, we show how an emerging focus
on two different arenas of rare genetic disease is subject to and a product of the dynamics
of inclusion and exclusion as this concerns participation in research and access to health
care. Sahra Gibbon carried out ﬁeldwork in three different cancer genetic clinics in urban
regions of Brazil in the southern part of the country between 2010 and 2012. This
included observations of clinical consultations and semi-structured interviews with
patients, health professionals and scientists. Waleska Aureliano carried out ethnographic
research in Rio de Janeiro, between 2012 and 2014. This included working with patients
and families linked to an Ataxia patients’ organisation, observing appointments in the
genetic service of a public hospital and formal meetings to discuss public policies related
to rare diseases.4
This article illustrates how attention to rare genetic disease in Brazil emerges at the
intersection of speciﬁc socio-historical and cultural dynamics. This includes a particular
history of genetic research and public health infrastructure, densely complicated feedback
loops between clinical care and research, patient mobilisation around the ‘judicialisation’
of health and recent state legislation regarding rare disease in Brazil.5 In examining these
intersections, we make a signiﬁcant contribution to an evolving ﬁeld of social science
research, highlighting the relevance of local conﬁgurations in the way rare genetic disease
is being made relevant for and by different communities. First, we outline how interest in
rare genetic disease has emerged within genetic medicine in Brazil, in dialogue with paedi-
atrics and oncology and in relation to a partial and inequitably distributed system of pub-
lic health. This has led to entanglements between research and clinical care resulting in,
but also made more complex by, the growing judicial demands for treatment from
patients as well as a recent national strategy to integrate genetics into public health. We
then draw on ethnographic research in Brazil examining two contrasting conditions in
which ‘rarenesss’ has been diversely situated and differently politicised: cancer genetics
and a class of degenerative neurological diseases known as Ataxias. In each of these cases,
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clinicians, patients and their families grapple with the slippery boundaries between
research and rights to health as well as the necessity and limits of care, therapy and pre-
vention. Collectively, these reﬂect and reproduce speciﬁc dynamics of inclusion and exclu-
sion. We demonstrate how these play out differently, even paradoxically, across and
within speciﬁc arenas of genetic medicine and how research and medical practice is
dynamically constituted by and helps shape the meaning of ‘rareness’. In the Brazilian
contexts we have examined, ‘rare disease’ is a ﬂexible categorisation that is made both
mutable and mobile; sometimes it is explicitly foregrounded or alternately it exists in ten-
sion with a discourse of disability or cancer as a common disease. In examining the situ-
ated meanings and strategic mobilisations of rareness, we underline the central
importance in Brazil of ‘biolegitimacy’ (Fassin 2009) and ‘rights’ to health care in the glob-
alisation of genomic medicine.
Genomics and rare genetic diseases in Brazil
In Brazil, medical genetics has only been recognised as a clinical and research specialty
since 1983. In 2013, the Federal Council of Medicine registered 200 medical geneticists
for the entire country, with 80% of them working in the south and southeast regions and
with four Brazilian states in the north of the country with no medical genetic services
(Scheffer 2013).
While the number of private genetic testing companies, particularly for paternity test-
ing, is expanding in Brazil, the majority of clinical services in medical genetics are concen-
trated in university or public hospitals within large urban centres or in reference centres
for research and/or blood donation (Melo et al. 2015; Horovitz et al. 2013). Somewhat
paradoxically, however, medical genetics in Brazil is not a domain of expertise that is fully
integrated into the public health care system, known as the Sistema Unico de Saude (SUS)
with the position of a medical geneticist not ‘ofﬁcially’ recognised (Vieira et al. 2013).
These professionals are usually based in university hospitals and research centres with vir-
tually none currently working in the primary health care. This situation is particularly rel-
evant in a context where the health system is de-centralised and hierarchical as it is in
Brazil. As a result, patients are obliged to go to primary health care centres to obtain ter-
tiary care services, such as genetic diagnosis and testing.
However, referral to the right medical specialist may be more complex as many doctors
do not know or recognise most of the rare genetic diseases that exist in the country. This
occurs particularly (but not exclusively) in people with late onset rare diseases. Currently,
the only way of mapping people suffering from genetic diseases is what is known as a live-
born declaration or declarac¸~ao de nascido vivo’ an ofﬁcial document issued by hospitals,
without which a child’s parents cannot register the birth of the child. While this certiﬁcate
records information about congenital abnormalities, the registry does not record people
that inherit genetic disease associated with adult onset conditions, such as Huntington
Disease or Machado–Joseph Disease (MJD), or even early onset genetic diseases, but
which may not be evident at birth.
Despite a scarcity both in terms of reference centres and professionals with expertise or
formal knowledge in medical genetics, since the 1990 s, there have been a number of
genetic health programmes. This includes the National Newborn Screening Program
(Programa Nacional de Triagem Neonatal—PNTN) created in 2001 that tests all
ANTHROPOLOGY & MEDICINE 13
newborns for four diseases: phenylketonuria, congenital hypothyroidism, cystic ﬁbrosis
and sickle cell disease and other hemoglobinopathies. The development of this pro-
gramme led to the establishment of national testing centres.6
Two medical ﬁelds are especially important in considering how efforts at incorporating
genetics into SUS have and are continuing to evolve: pediatrics and oncology. The ﬁrst
advocates wider coverage of the newborn screening programme, to include more diseases,
and also the integration of genetic counselling into primary health care. The aim is to
reduce the number of newborns with congenital anomalies that in the year 2000 was the
second cause of death in children under one year of age in Brazil (Horovitz et al. 2013). In
the case of oncology, cancer genetics has developed in Brazil over the last 10 years in deep
and complex relation to research and public health services, as discussed below.
In Brazil, genetic research related to cancer and pediatrics, are directly connected to the
national system of free and universal public health. For the most part, monetary and
research investments for genetic diseases in Brazil comes from the public sector, especially
the federal government, and also via networks of transnational research. Somewhat con-
tradictorily, the State part funds research in the context of a clinical genetic service not
only considered insufﬁcient by doctors and patients but which is itself mostly sustained as
a result of research funds. Until recently, only a few rare genetic diseases were included in
SUS treatment protocols (among them Osteogenesis Imperfecta, Cystic Fibrosis and
Gaucher Disease). Some drugs used to treat these conditions are included in the list of
high-cost medicines approved by the National Health Surveillance Agency (Age^ncia
Nacional de Vigila^ncia Sanitaria—ANVISA). However, even in these cases many families
affected by rare genetic diseases may need to initiate what are known as judicial demands
to obtain the drugs.
Judicialisation, research and public policies for rare diseases in Brazil
The ‘judicialisation’ of health has become a growing phenomenon in Brazil over the last
10 years, involving persons from a range of social classes (Biehl 2013). The constitutional
commitment by the State to provide health care to all Brazilians citizens has led many
families, individuals and sometimes also patient associations affected by rare diseases to
seek the right to certain health care products and services, through legal tribunals. These
claims range from access to drugs not approved by ANVISA, to high-cost medicines not
included in SUS lists, to increasingly genetic tests and also in some cases the ‘right’ to take
part in experimental clinical trials (Castro 2015; Diniz, Medeiros, and Schwartz 2012).
Despite ﬁnancial and structural limitations, Brazilian patient associations have been
active and highly inﬂuential in political lobbying resulting in the construction of public
policies directed at people living with rare diseases. However, it is important to note how
in contrast with many Euro-American patients’ associations (Huyard 2009; Rabeharisoa
et al. 2014), Brazilians groups are not necessarily motivated to ﬁnd a ‘cure’ for rare dis-
eases. The focus of their actions is rather to ‘oblige’ the State to support and fund health
care services for those with rare diseases and their families (Grudzinski 2013; Aureliano
2015). In many cases, this means access to high-cost medication. Since the 1990 s, after
the creation of the Brazilian public health system, there have been several successful
achievements, directly stemming from the participation of patients’ associations, to
increase attention to rare or rather neglected diseases. For example, the current public
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health care policy for sickle cell disease (SC) was developed following strong lobbying by
patients’ organisations and particularly the Brazilian Movimento Negro or Black Move-
ment, due the historical link between SC and black populations (Silva 2014). As a result,
SC is now one of the diseases tested by the national programme of newborn screening. A
similar scenario occurred with Gaucher’s disease, where drugs used to treat the condition
were included in the National Exceptional Drugs Program following litigations pursued
by affected families against the State.
In 2009, the Directive 81/09 from Ministry of Health established a National Policy of
Comprehensive Care in Medical Genetics. The aim was to create public health pro-
grammes that offered genetic counselling and testing. This was, however, thwarted by
operational and conceptual problems including the scarcity of health professionals with
knowledge in medical genetics.
Analysing these developments, Novoa and Froes Burnham (2011, 65) call attention to
the relevance of distinguishing medical genetics that is ‘important and applicable to public
health and that which is still object of research’. However, in practice, this separation has
not proved easy or sustainable in Brazil since many research centres depend on biological
material collected in the clinics. In turn, many patients depend on research to obtain a
conclusive diagnosis for diseases without cure or treatment, which might nevertheless, for
example, guarantee rights, such as accessing certain state beneﬁts. Due to the lack of deﬁ-
nition of norms regarding their medical utility and the difﬁculty of disentangling the aims
of research and public health, genetic tests are seen as a great challenge for public policy.
The situation is even more complex for asymptomatic subjects where knowledge of risk
cannot always be directly linked to preventative health care treatments or interventions.
More recently in Brazil, the joint action of government, scientists, physicians and asso-
ciations has led to the development of the National Policy for Comprehensive Care of Peo-
ple with Rare Diseases (PNAIPDR), instituted through Directive 199, published in January
2014.7 It provides a mandate for the creation of medical genetics referral services that
include primary health care and which are equipped to provide specialised care for people
with rare diseases. To achieve these goals, various actions and procedures will need to be
created within the public health system, including expanding the list of medications
offered and widening the scope of genetic testing and counselling. As some patient associ-
ations have already stated, the current challenge is to ensure the policy is fully enacted,
something which did not happen in the case of Directive 81/09.
However, the PNAIPDR also envisages that it is the duty of the Ministry of Health to
ensure the development of research that contributes to technological innovation and dis-
semination of knowledge related to promoting health, prevention, care and rehabilitation
of people with rare diseases. This is an important issue for many medical genetic profes-
sionals who frequently work in and must negotiate the liminal space between clinical care
and research. In this new scenario, many researchers and patient advocates argue that the
same ethical principles and legislation for researching non-rare disease would make it
almost impossible for Brazilian patients to take part in clinical trials sponsored by interna-
tional laboratories.
An important illustration of these difﬁculties is provided by Castro’s (2015) analysis of
a public consultation undertaken in 2011 to review Resolution 196 of the National Coun-
cil of Health that deﬁnes the ethical principles of research with human beings in Brazil.
One of the stated norms of this resolution relates to the duty of research sponsors to
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provide for patient research subjects the best therapeutic, diagnostic and prophylactic
methods identiﬁed in the clinical trials, for an undetermined time. This premise aims to
reduce judicial claims against the State to access experimental drugs that are not yet
approved by Brazilian health organisations.
Most of the 300 commentaries from the public consultation in response to this new
regulation came from doctors, but also from patients and families affected by rare dis-
eases. According to many of those who responded, the mandate to provide such services
to patient subjects would reduce the probability of national and international commercial
laboratories conducting clinical trial research with Brazilian patients with rare diseases.
Freely supplying the drugs that resulted from patient involvement in research would, crit-
ics of the resolution argued, make commercial investment unfeasible and unappealing. As
a result, many doctors and patients claim that speciﬁc ethical principles should be devel-
oped for clinical trials conducted with rare disease patients. Most striking in these argu-
ments is the way that clinical trials are compared to treatment.8
The concept of ‘rareness’ acts here as an important issue in these debates. Similar to the
displacement realised by the pharmaceutical industry in Europe between proﬁt and inno-
vation in the context of rare diseases as examined by Huyard (2009), we can say that, in
Brazil, there is a displacement between clinical research and treatment/health services in
an effort to participate in global genomic research initiatives that meet international ethi-
cal standards of human subject research.9 This has particular consequences for patient
and health care provision especially when, as Castro (2015) points out, to be included in a
clinical trial may be the only hope for those who have diseases for which there are cur-
rently no treatments or cures.
In the next section, we examine in more detail how some of these aspects are unfolding
in relation to contrasting domains of attention to rare genetic disease in Brazil, cancer
genetics and a particular class of neurodegenerative disorders know as Ataxias.10
Oncogenetica in Brazil; between common conditions and rare genetic
syndromes
While the range of diseases addressed within Brazilian cancer genetics is broad, in this
article we examine two speciﬁc avenues of inquiry. This includes the high-proﬁle context
of BRCA genes associated with breast cancer and a particular biomarker R337h located
on the TP53 gene that has been identiﬁed in the south and southeast of Brazil and associ-
ated with what is normally thought to be a ‘rare’ cancer syndrome known as Li-Fraumeni.
Cancer genetics is not currently included in the Government Directive to incorporate rare
genetic disease into the public health. Nevertheless, examining these domains of Brazilian
cancer genetics illuminates how what becomes part of the terrain of research and care is
informed by strategic mobilisation of articulations of ‘rareness’. This is constituted as cur-
rently ‘unknown risk’ in the case of the BRCA genes or in terms of a disease which is both
‘rare’ and ‘common’ in the case of R337h. At the same time, there are also contrasting cul-
tures of activism in these different areas of cancer research where ‘rights’ to health care are
articulated in speciﬁc ways.
The specialism of cancer genetics has emerged in Brazil in the last 10–15 years linked
to research and university hospitals predominantly, although not exclusively, in the rela-
tively wealthy southern urban centres. While this regional and institutional location
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reﬂects differential national cancer incidence, it is also a product of and informs a system
of ‘hidden innovation’ (Souza 2015) in which clinical interventions are entangled with
and dependent on national and transnational research funding. The dense inter-relation-
ship between research and the clinic has been described by others as a characteristic fea-
ture of the ‘clinical collectives’ that have emerged in ‘translational’ cancer genetics in
many national contexts, where the boundary between clinical care, research and innova-
tion is highly diffuse (Bourret 2005). In resource-poor contexts such as Brazil, dependency
on national and transnational research investment has particular consequences for the
way that an ethic of care (Gibbon 2015) and of ‘solidarity’ (Souza 2015) become folded
into the pursuit of cancer genetics.
The productive uncertainty of unknown (‘rare’) BRCA variants and common
cancers
In Brazil, research focused on the two high-proﬁle inherited susceptibility genes BRCA 1
and BRCA 2 has been a signiﬁcant domain of activity, including efforts to identify poten-
tial founder mutations. Brazilian research examining internationally well characterised
mutations on the BRCA genes has been directly facilitated by transnational collaborations
examining how genetic ancestry may variably contribute to the high rates of cancer in the
southern region of the country. It is a goal which co-exists alongside a desire to develop
quick and cheap means of expanding the scope of genetic testing in Brazil in the context
of public health concerns about the rising rates of cancer in the country (Gibbon 2015).
Yet, common founder mutations linked to the BRCA genes have not been identiﬁed with
any great frequency. It is a terrain of research and medical intervention which is as a result
in Brazil (as elsewhere), characterised by a large amount of uncertainty with the frequent
identiﬁcation of unknown mutations and what are described as ‘Variants of Unknown
Signiﬁcance’ or VUS.
For many members of the cancer genetic community in Brazil, this is a situation of
‘unknowing’ that warranted further urgent investment in cancer genetics. There has been
a strong lobbying group of health professionals linked to specialist cancer and university
research hospitals, which have been campaigning for some time for the incorporation of
cancer genetics within the SUS public health system. This has coalesced around networks
such as a national Hereditary and Familial Cancer Network, which have consistently
emphasised the ‘speciﬁcity’ of the Brazilian population (INCA 2009).
The identiﬁcation of speciﬁc variants of unknown risk, while generating clinical uncer-
tainty, can also facilitate particular avenues of research. For example, during ﬁeldwork
undertaken by Gibbon, the discovery of a variant on the BRCA genes normally associated
in the scientiﬁc literature with ‘African American Ancestry’ caused a degree of unease and
hesitancy among Brazilian researchers concerning how this should be communicated at
the clinical interface to patients. At the same time, it also extended and generated novel
transnational research collaborations and networks (Gibbon 2016). As Brazilian cancer
genetic practitioners negotiate the issues concerning ‘missing heritability’, ‘under-served
populations’ and also engage with the increasing stratiﬁcation of cancer in translational
research, their efforts to localise unknown variants on the BRCA genes as forms of ‘rare’
disease may yet prove a viable means of extending networks of research.
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Yet, it is also important to note how the identiﬁcation in Brazil of multiple variants on
the BRCA genes of unknown or uncertain signiﬁcance also have consequences beyond
the speciﬁc disciplinary conﬁnes of cancer genetics. While productive research and clini-
cal collaborations between oncology and genetic specialists may unfold as a result of these
developments, it is not guaranteed. In one hospital included in research undertaken by
Gibbon, those working in mastology (a clinical sub-discipline with an established history
in Brazil) resisted efforts to include predictive genetic testing interventions in their clinical
repertoire. This did not, in their view, contribute to the wider goals of addressing the high
rates of breast cancer in Brazil. As one Brazilian mastologist put it,
If you don’t have information about the criteria for risk assessment in Brazil, you’re going to
start wasting money and we don’t really have money to waste here, even more so in the pub-
lic health system!
In a resource-limited public health system, where addressing basic health care issues
related to ‘common’ diseases such as breast cancer are a signiﬁcant challenge, these com-
ments underline differences in responses to genetic interventions. This raises further ques-
tions about what kinds of ‘bio-clinical collectives’ (Bourret 2005) can coalesce around
genomic knowledge and the extent to which attention to ‘rare’ or unknown genetic var-
iants associated with cancer risk limit or mobilise different medical specialities.
R337h, ‘rare’ cancer syndromes; speciﬁcity as inclusion
Another prominent domain of inquiry within Brazilian cancer genetics has focused on a
particular variant described as R337h, located on the TP53 gene. Aligning and extending
particular kinds of national and transnational research collectives, this is an arena of
research where engagement with (and contestation of) ‘rareness’ has been both highly vis-
ible and productive.
Common germline mutations on the TP53 gene are infrequent, estimated in the US to
be around 1 in 5000 but which are associated with a rare cancer syndrome known as Li-
Fraumeni that has been linked to an up to 90% lifetime chance of developing different
types of cancer, particularly in children (Malkin et al. 1990). Brazilian studies in the
early 2000s suggested that a speciﬁc variant R337h located on the TP53 gene is particu-
larly frequent in the south of the country, with a purported prevalence of 1 in 300 in these
regions. It has been initially associated with a range of rare childhood cancers and
subsequently with more common adult cancers, including breast cancer (Giacomazzi
et al. 2014).
The prevalence of the mutation in the southern region of the country has been of sig-
niﬁcant interest for members of the cancer genetic and paediatric community in their
effort to constitute this as a signiﬁcant public health issue and coalesce national and trans-
national research interests. The attempt to deﬁne the nosology of the syndrome has also
entailed shifts between an association and contrast with the normally ‘rare’ syndrome Li-
Fraumeni and more common cancers such as breast cancer. Moreover, while heated
debates continue about the association of R337h with adrenocortical cancers in children
and/or other common cancers in adults (see Achatz, Hainaut, and Ashton-Prolla 2009),
innovation and investment have continued in this ﬁeld. This includes efforts in 2013 to
develop a cheap and rapid testing technology for mass screening of R337h (Arruda and
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Sensato 2013) and evolving epigenetic research which locates R337h in wider programmes
of international research in Brazil concerned with metabolism and cancer (Armstrong
2015). Like the terrain of BRCA genetics, research on R337h is also subject to uncertainty
which has nevertheless become part of an extended and broad terrain of research inside
and outside Brazil. In the case of R337h, this has successfully aligned diverse specialisms
including cancer genetics, paediatrics and now increasingly epigenetic research. Signiﬁ-
cantly, many members of the clinical and research teams involved in the Brazilian cancer
genetics community commented that it was research related to R337h, rather than the
high-proﬁle terrain of BRCA genetics, which they felt was most likely to facilitate the
expansion and consolidation of cancer genetics as a medical speciality in Brazil. This was
how one member of a research team in Sao Paulo put it,
I think it (R337h) will be a major issue here in Brazil, because it is very frequent, much more
frequent than BRCA mutations and the problem is that BRCA testing is also much more
expensive than TP53. The thing is we have a pathway and a possibility for doing R337h.
Whenever I have a patients with this diagnosis, I can see right away I can collect the sample,
test it and right away give that patient a result.
While the BRCA genes have been directly associated globally with the high incidence of
common cancers such as breast and ovarian cancer, which are rising at alarming rates in
Brazil, ‘rareness’ is nonetheless implicitly highlighted in relation to what are ‘unknown’
genetic variants. By contrast, in relation to the normally ‘rare’ cancer syndrome Li-
Fraumeni, the ‘speciﬁcity’ of the syndrome in Brazil is explicitly foregrounded and has
successfully aligned diverse medical specialists. At the same time, the rareness of the
syndrome in Brazil is directly contested, with an emphasis on the national and regional
frequency of R337h, described as a ‘conditional cancer pre-disposing mutation’.
Therefore, in the case of BRCA genes and R337h there is a productive movement and jux-
taposition between the frequency and rareness of gene variants, diseases and syndromes
that reﬂect and constitute speciﬁc avenues of inclusion and exclusion.
Cultures of activism, ‘under-served’ populations and judicial rights to genetic
testing
The cultures of activism around articulations of ‘rights to health care’, that have emerged
somewhat differently in the context of research and medical interventions related to
BRCA and R337h, provide another illustration of how diverse aspects of cancer genetics
in Brazil are subject to different dynamics of inclusion/exclusion.
The way that cancer genetics operates at the interface between research and public
health has particular consequences for how patients and others are ‘active’ in pursuing
rights to health care interventions. Observations in clinical contexts illuminated how in
the case of BRCA genetic testing a handful of patients and families in Sao Paulo, had
pooled ﬁnances to be able to pay for a genetic test or were negotiating with their private
health insurer to secure rights to screening and testing.11 By contrast, there was a striking
absence of this kind of ‘activism’ among so called ‘R337h patients.’ Many of those
recruited into this particular research terrain were SUS patients without private health
insurance and often very little access to basic health care facilities, particularly those fami-
lies who came from the interior rural regions.
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Nevertheless, a different sort of activism was manifest in this arena. This was nurtured
and pursued by health professionals in a context where research has become entangled
with an effort to provide what is seen as ‘preventative’ public health care for patients who
were currently ‘under-served’. One particular manifestation of such activism was evident
in what were described by researchers as ‘road trips’ undertaken by clinical and research
teams to rural parts of the country to meet large extended families affected by cancer
linked to the R337h mutation.
In one ‘road trip’, that Gibbon participated in, a visit to a family home in the rural area
of the state of Sao Paulo had been facilitated by a young female patient who had been
treated for cancer and also identiﬁed as having the R337h mutation. One Saturday morn-
ing in 2011, an array of relatives squeezed into the small sitting room of the patient’s aunt
to hear the information about the research from the lead practitioner. After explaining
the details of the research where the speciﬁcity (if not explicitly the rareness) of the syn-
drome Li-Fraumeni in the south of the region was emphasised, and discussing consent
with those who wanted to participate, over 20 samples were collected from the large
extended family. The excitement that ensued for the clinical team in being able to calibrate
and extend research related to R337h, was also however deeply entangled with their sense
that incorporating extended family members into research was a means of providing
neglected preventative health for ‘under-served’ communities. The only ‘care’ that could
be offered to relatives was mostly dependent on identifying the presence of deleterious
variants. However, the promise of future health provision, including, for instance, routine
mammography screening within a highly regarded specialist cancer hospital, was often a
sufﬁcient justiﬁcation and reason to participate for many family members.12 In these sit-
uations, the gratitude of patients in being part of research initiatives was common. As one
patient put it, in addressing the researchers during another community event that aligned
affected families, care and research, ‘you are doing so much for us, what can we do for
you?’.
While the ‘activism’ of practitioners in Brazilian cancer genetics seems to directly
inform who and what gets encompassed within terrains of research and medical care, the
expanding scope of judicialisation, in conjunction with the complex dynamics of research
and health care in Brazil, is further shaping these dynamics.
In 2013, during a return ﬁeldwork trip, Brazilian clinicians working in both public and
mixed public/private hospital talked about the upsurge in judicialisation cases linked to
rights to obtain genetic testing for the BRCA genes. Most directly commented that they
felt this was as a result of the announcement by the actress Angelina Jolie a few months
previously that she had had a BRCA test and undergone a prophylactic mastectomy. The
discourse of ‘rights’ to testing, that had ensued at this time in the international media and
press, was pervasive in Brazil and elsewhere leading to a national and indeed international
increase in referrals to cancer genetic clinics (Evans et al. 2014). One clinician commented
that of the 30 or so patients she had seen each week in the clinics at least one was now
pursuing the judicial right to have a genetic test for the BRCA genes.
With currently no high proﬁle-celebrity endorsing the ‘right’ to genetic testing and
given the dearth and complexity of ‘preventative’ and prophylactic treatment interven-
tions for a variant that is thought to lead to a multitude of cancers, it is not surprising to
ﬁnd that there are as yet very few judicialisation cases related to R337h. Yet, as the exten-
sive ‘bioclinical collective’ (Bourret et al. 2005) which has emerged around the ‘common’
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biomarker R337h associated with the ‘rare’ syndrome Li-Fraumeni evolves, and as the
emerging horizon of different therapeutic and/or preventative screening interventions
becomes clearer, this situation may change. Thousands of cases of judicialisation in Brazil
are being processed by the courts not only for therapeutic treatments for rare genetic dis-
ease but also now for testing and screening for more common conditions. It seems likely
that this will increasingly be an avenue by which those currently excluded from health
care services, such as the signiﬁcant and large numbers of Brazilians who are carriers of
R337h, will seek to change and inform the parameters in which their rights to screening,
testing and monitoring may be included.
In summary, even though cancer genetics is excluded from the recent Brazilian Gov-
ernment Directive to incorporate rare genetic disease into the public health system, differ-
ent sorts of ‘activism’ and participation by researchers and patients inform how cancer
genetics is nonetheless subject to speciﬁc dynamics of inclusion (and exclusion) related to
research and health care access.
From ‘rareness’ to ‘disability’, and vice-versa: the case of Ataxias
Ataxia is the name given to a series of degenerative neurological diseases that mainly affect
movement and speech. Though various acquired forms of the disease exist, the majority
are genetic and hereditary in origin. Machado-Joseph Disease is one of the inherited forms
of Ataxia and was ﬁrst identiﬁed in the medical literature in the 1970s, although it was
only in the 1990s that it was genetically characterised. Initially, the disease was reported
in North American families that were descended from Azoreans. While the prevalence of
the condition in Azores’ Islands is very high, current studies suggest that the genetic
mutation linked to MJD is present in other ethnic groups (Lopes-Cendes et al. 1997). It is
an autosomal dominant inherited disease, which means that the probability of transmis-
sion to descendants is 50%. Generally speaking, MJD manifests in adult life around the
age of 40, with principal symptoms including loss of balance, muscular paralysis, speech
problems, difﬁculty in swallowing and double vision. Affected people can live for decades
while the disease evolves before dying mainly from secondary complications. There is no
curative treatment for MJD. Therapeutic interventions like physiotherapy and speech
therapy aim to minimise the effects of the disease, which eventually leads to bodily
paralysis.
In Brazil, this is the most frequent form of hereditary Ataxia, with a high prevalence in
the south of the country, associated with Azorean immigration to this region. In the
southern state of Rio Grande do Sul (RS), MJD represents 78% of all inherited Ataxias
registered in this state (Saute and Jardim 2015). RS has a high concentration of families
affected by MDJ, with a prevalence of 3 people to every 100,000 inhabitants. (Trott et al.
2006). It is in this state that the main Brazilian medical genetic laboratories and research
groups are located, with 37 of the 50 physicians with specialisation in medical genetics
based in RS (Scheffer 2013, 249). This regional focus that combines research about and
care for those with MJD has stimulated further discussion about the complex intersections
between research agendas and clinical care.
The Porto Alegre Polyclinic Hospital, for example, conducts tests for patients from a
number of Brazilian states, employing resources and professional staff linked to a research
project run by the Federal University of Rio Grande do Sul (UFRGS). The project’s main
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objective is to make the molecular investigation of neurogenetic conditions available for
individuals from diverse parts of Brazil, forming a national research network on such dis-
eases. Today, 11 hospitals are linked to this network,13 through which many people with
symptoms of inherited Ataxias can get a diagnosis for their diseases.
Rio Grande do Sul is also the location for INAGEMP (The National Institute of Medi-
cal Population Genetics) that is part of the National Institute of Science and Technology
created in 2008 by the federal government. Such institutes aim to develop innovative
research and produce national patents, connecting research centres from different regions.
The network created by INAGEMP includes some groups dedicated to investigating
MJD14 in partnerships with Portuguese researchers since Portugal and the Azores have a
high incidence of MJD, and because colonisation is considered a central factor in the
development of the disease in Brazil.
Brazilian research on MJD investigates a range of aspects, including molecular dimen-
sions and phenotypic variability (Saute and Jardim 2015), the implications of predictive
tests for asymptomatic individuals from affected families and the need for genetic coun-
selling (Schuler-Faccini et al. 2014). Studies on medications to control or delay the course
of the disease (Monte et al. 2003; Saute et al. 2014) have not yet observed improvements
in patients’ health, despite increased knowledge of hereditary Ataxias.
Studies with stem cells elsewhere, outside of Brazil, have indicated a relative improve-
ment, but without any conclusive ﬁnding. These are studies undertaken without control
groups and with patients affected by different types of Ataxia, which make it difﬁcult to
validate the research for speciﬁc groups in contexts such as Brazil (Saute and Jardim
2015). Most of them were conducted in countries, such as China and Thailand, with more
ﬂexible regulations concerning research and therapeutic use of stem cells and which pro-
mote so called ‘stem cell tourism’ (Murdoch and Scott 2010). It is notable that in 2015, a
Brazilian lawyer with MJD successfully litigated against the Brazilian government to
demand that they pay for his treatment with stem cells in Thailand.15 Based on this deci-
sion, in March 2016, a patient with Friedreich’s Ataxia managed to reverse a judicial deci-
sion which had originally denied her demand to a similar treatment, which will now also
be paid by the Brazilian government.16
Nevertheless, this kind of demand is not common among MJD patients in Brazil,
where there is also no active mobilisation of patients’ organisations for the development
of clinical research to ﬁnd a cure for the disease or to access predictive tests. The main
concern of Ataxia patients in general, and speciﬁcally of MJD carriers, is focused on mini-
mising the effects of the disease, and the creation of speciﬁc clinical protocols to attend to
their health care needs.
One avenue for achieving these aims for those affected has been to frame health care
needs through approaches developed previously by those with disabilities. According to
Monsores (2013), the increasing attention to the treatment of rare diseases in SUS was
indirectly linked to the National Health Policy for Disabled People. This policy was cre-
ated in 1989, and among its many guidelines was the stated responsibility of State to pro-
vide access to detect genetic diseases that can cause disability and offer genetic
counselling to families. However, at that time it was not possible to achieve these objec-
tives as there were insufﬁcient genetic counsellors and medical geneticists to adequately
structure and implement the policy.
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Nevertheless, it is notable that recent government actions related to rights of disabled
people are increasingly being encompassed also with reference to rare diseases. Recently,
the Parliamentary Commission of Defense of the Rights of Disability People, approved a
project that equates another disease, neuroﬁbromatosis, to other physical and intellectual
disabilities. The project will be examined by other commissions of Parliament and, if
approved, will ensure the same social rights to people affected by neuroﬁbromatosis as
those who are disabled.17 In March 2016, a new Parliamentary Front focused on Rare Dis-
eases in the Chamber of Deputies was announced aiming to promote political debate
about people with rare diseases, and construct an agenda to guarantee their access to
health services, exams and diagnosis.18
While these developments suggest that the association between ‘rare diseases/disability’
to promote ‘right to health’ and ‘social inclusion’ is automatic, this is far from being the
case. More often, this has to be assembled between several actors as part of an uneven
negotiation between patients’ organisations, politicians and health professionals. How-
ever, the link between disability rights and genetic research linked to rare diseases is par-
ticularly visible, in relation to diseases that affect children. Some researchers go so far as
to defend actions to control rare diseases as a way to reduce the number of those with deﬁ-
ciencies among the population (Santos et al. 2013). While also raising the problematic
issue of illegal abortion in cases of malformation or congenital anomalies, without other
therapeutic options, genetic counselling and predictive tests are often seen as the main
avenues for reaching this goal (Schuler-Faccini et al. 2014).
Nonetheless, some studies suggest that there is also a reluctance to undertake genetic
testing or even receive genetic counselling, especially among asymptomatic subjects in
families of those with MJD and other neurodegenerative diseases (Aureliano 2015; Osada
2012). In Brazil, this reluctance must be understood in relation to a complex set of varia-
bles linked to limited access to genetic tests in the public health system, the lack of thera-
peutic options to treat diseases identiﬁed by testing, the prohibition of abortion in cases of
congenital abnormalities, the high cost of assisted reproduction techniques to select
embryos (e.g. PGD Pre-Implantation Genetic Diagnosis) and the particular moral or reli-
gious restrictions related to contraception, among certain communities. In contrast to
some hereditary cancers, notably those associated with the BRCA genes, there are addi-
tionally no preventive or prophylactic options for asymptomatic individuals undertaking
predictive genetic testing for MJD.
In her research with families affected by MJD in Rio de Janeiro, Aureliano (2015)
observed that people seek genetic testing when they start to experience the ﬁrst symptoms
of disease and also when they are seeking to justify leave from work or to access disability
beneﬁts. Two frequent symptoms of MJD are an imbalanced gait and slurred speech, and
as a result many carriers are mistakenly taken to be drunk. Here, genetic tests also become
a way to avoid this stigmatised identiﬁcation, especially for men in their work environ-
ments. As one patient put it,
Had I said before [the test when the symptoms were milder] they would have said I was
shirking, because I didn’t look like I had any kind of disease […] Had I gone about telling
everyone I had the disease, I would have been labelled a shirker (M., 54, retired after ﬁve
years living with symptoms)
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Asymptomatic relatives were also not keen to obtain predictive tests. This was often
because of the lack of a cure or because it was felt positive results might negatively affect
the person, provoking depression and anxiety, which it was believed might itself lead to
early onset of MJD.
In our family we are only opposed to ‘this testing thing’. We know that for those that have
this disease it’s like an electronic device that comes out of the factory with a defect and is
irreparable. If there is no cure, no treatment, why test before? (A., 64, asymptomatic, married
with a cousin affected by disease, mother of two adult men, grandmother of two girls, none
of them undertook predictive tests).
Reproductive planning based on genetic tests was not a concern to members of a num-
ber of families Aureliano investigated. However, other strategies were used to minimise
risks or the appearance of disease in adult life, as these comments suggest.
I always thought that I had to have a job ﬁrst [before getting pregnant], a good job, that
would allow me to live, and if the disease appeared, one that would enable me to pay for a
health plan for me and my child. (S., 37, asymptomatic, not tested, trying to get pregnant.
Her mother and uncle have MJD).
Most rare diseases cause some kind of physical and/or intellectual impairment. Taking
this into account, the association between ‘rareness’ and ‘disability’ appears as a justiﬁable
strategy to get health access and other rights. However, this association is not immediate
or consistent as the evidence demonstrated here suggests. In the case of MJD, for example,
it becomes difﬁcult to measure the level of handicap because the disease is unevenly pro-
gressive. The development of symptoms may be gradual in the ﬁrst years, which makes it
difﬁcult to categorise some limitations as deﬁciency (for example, slurred speech). The
heterogeneous phenotype of MJD can restrict access to certain rights guaranteed for dis-
abled people, this includes, for example, special beneﬁts to be paid in retirement in Brazil,
whose value differs according to the level of handicap of the person.
On the other hand, in face of limited therapeutic options, the carriers of hereditary
Ataxias in general have found in the policies and political attention to disabled people an
avenue for social and political inclusion. Health professionals working with MJD patients
have also mobilised around disability as an important means to offer more regular health
care to their patients and to make it easier to access social rights.
Despite this, the ‘rareness’ of Ataxias is still the category and description normally used
to frame the condition for patients and researchers, rather than its direct association with
disability. In her research, Aureliano rarely observed those affected by MJD deﬁning
themselves as disabled, or afﬁrming that there was a ‘deﬁciency’ in their family.
Rather, they would frequently state that they carried or that their family had a rare disease.
Nonetheless, her interlocutors demanded and used many social rights linked to disability,
such as the electronic card that offers free use of urban buses.
This suggests that both categories, ‘rare’ and ‘disabilities’ are extended and limited to
accommodate the speciﬁcities and variability of rare genetic diseases, thereby constituting
various domains of inclusion and exclusion in the context of health care policy, politics
and scientiﬁc research in Brazil. If the ﬁeld of rare diseases offers possibilities for the
future, with particular potential for innovation linked to genomics, the ﬁeld of disability
connects with the actual day to day realities of those affected by such conditions. Here,
the capacity to offer care today is foregrounded by patients and also sometimes by
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professionals, rather than only the hope for a cure, which remains currently unknown and
uncertain.
Conclusion
In this article, we have examined how an emerging focus on rare genetic disease in Brazil
is subject to and a product of particular dynamics of inclusion and exclusion at the inter-
face with an expanding terrain of globalising genomic research and medicine.
In Brazil, a focus on rare genetic disease has emerged alongside the ﬂedgling speciality
of genetic medicine in close and complex relation with the goals of research and public
health. This blurred boundary between research and clinical care has facilitated, but is
now also challenged, by the growth of health judicialisation in Brazil; something which
the recent national strategy to integrate rare genetic disease into the SUS public health sys-
tem aims to resolve. In a context, where the state needs to manage limited resources to
allow universal access to health care, as well as recognise the speciﬁcity of genetic diseases
whose aetiologies and population frequencies are often contested or unknown, rareness
can become a means to promote social justice and health care rights. The expanding ter-
rain of judicialisation in Brazil makes this very evident. Yet, we have also seen how an
association with rareness can lead to different sorts of potential or real exclusions, as
entailed by the ethical responsibilities for treatment in the context of clinical trials in Bra-
zil. While we recognise that this is an arena of development in which a range of different
social stratiﬁcations inform the ability to leverage access to health care, partly in relation
to income, social class and education, we argue that the ‘politics of difference’ at stake in
Brazil stands in contrast to the politics of ‘inclusion’ as described by Epstein (2007) for
the US. While in the latter, race and gender appear to more explicitly shape this process,
in Brazil this is also informed by a politics predicated on efforts by patients, families and
patient support organisations to oblige the state to meet a constitutional commitment to
provide health care to all.
In the case studies we have explored of cancer genetics and Ataxias in Brazil, there are
contradictory yet also productive movements that serve to both stabilise and destabilise
research and medical practice related to these conditions within the parameters of ‘rare’
genetic disease. In the case of cancer genetics, we see how the pursuit of research and medi-
cal diagnosis related to the BRCA genes or R337h can be both enabled through an associa-
tion with ‘rare’ cancer syndromes such as Li-Fraumeni or ‘unknown’ genetic variants in the
case of BRCA genes. But this is also achieved through situated association with reference to
the ‘frequency’ of the biomarker R337h in the south of the country or common cancers
such as breast cancer. While in some cases an association with cancer as a common disease
might lead to novel possibilities in terms of judicialised claims by certain enabled publics in
the case of the BRCA genes, there are (at least currently) also limits to such possibilities in
the case of R337h. In the case of Ataxia in Brazil, we see how there is a different kind of
movement among researchers, patients and families between constituting the disease as
‘rare’ and/or associated with a wider class of disabling conditions in various situated con-
texts. The legitimacy of rights to health care resources and services (not always or necessar-
ily cures, diagnosis or treatment, but also services and support) are made evident here as
those living with conditions such as Ataxia or providing care for them negotiate different
terrains through which mostly basic health care needs can be met.
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By drawing attention to the parallel and contrasting movements in the dynamics
between inclusion and exclusion in the case of cancer genetics and Ataxia in Brazil, we
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